EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others)



Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others)



Journal of Hepatology 39 Suppl 1: S172-S176




(PDF emailed within 1 workday: $29.90)

Accession: 050833187

Download citation: RISBibTeXText

PMID: 14708699



Related references

The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b. Pakistan Journal of Pharmaceutical Sciences 28(4 Suppl): 1493-1497, 2015

The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment. Acp Journal Club 144(1): 4-4, 2006

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Alimentary Pharmacology & Therapeutics 23(3): 409-419, 2006

Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 143(3): 629-36.E1, 2012

De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients. Hepatology International 5(2): 671-676, 2011

Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scandinavian Journal of Gastroenterology 47(4): 475-481, 2012

Predicting HBeAg loss by HBV DNA early kinetics and HBV genotype during treatment of HBeAg+ chronic hepatitis B patients with adefovir dipivoxil. Journal of Hepatology 38(Supplement 2): 26, April, 2003

Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B. Gastroenterologia Y Hepatologia 29(2): 71-73, 2006

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clinical Therapeutics 30(2): 317-323, 2008

Treatment of HBeAg negative chronic hepatitis B with new drugs. Journal of Hepatology 39(Supplement 1): S172-S176, 2003

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131(6): 1743-1751, 2006

Efficacy and safety of peginterferon alfa-2a (40 kd) plus adefovir for 96 weeks in HBeAg-negative chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 21(7): 498-501, 2014

Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. World Journal of Gastroenterology 13(30): 4096-4099, 2007

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45(2): 307-313, 2007